Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

SHP-1 (PTPN6) Gene Supression by FLT3/ITD Defines an Aggressive Subgroup of Myeloid Malignancies.

Armando V. Mena-Duran, MD, Juan C. Pajuelo, MSc, Jose Cervera-Zamora, MD, Zaida Garcia-Casado, PhD, Ana Valencia, MSc, Eva Barragan, PhD, Luis Benlloch, BSc, Tomas Mustelin, MD,PhD, Guillermo Sanz, MD,PhD, Miguel A. Sanz, MD,PhD

Blood (2006) 108 (11): 1907.

https://doi.org/10.1182/blood.V108.11.1907.1907

Published: 2006

Journal Articles

Autologous Stem Cell Transplantation after FLAG-IDA Chemotherapy for High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemias Secondary to MDS (sAML) Does Not Improve Outcome: A PETHEMA Experience in 103 Patients.

Guillermo F. Sanz, MD, Armando V. Mena-Duran, MD, Jose M. Ribera, MD, Teresa Bernal, MD, Luis Palomera, MD, Maria C. del Cañizo, MD, Mar Tormo, MD, Maria J. Sayas, MD, Raimundo García-Boyero, MD, Javier de la Serna, MD, Manuel Pérez-Encinas, MD, Montserrat Pérez-Sánchez, MD, María J. Arilla, MD, Juan J. Moneva, MD, Maria L. Amigo, MD, Luis Benlloch, Montserrat Batlle, MD, Consuelo Rayon, MD

Blood (2005) 106 (11): 793.

https://doi.org/10.1182/blood.V106.11.793.793

Published: 2005

Journal Articles

Identification of Risk Factors for Tumour Lysis Syndrome in Patients with Acute Myeloid Leukaemia: Development of a Prognostic Score.

Pau Montesinos, MD, Guillermo Martin, MD, Mariluz Perez-Sirvent, MD, Armando V. Mena-Duran, MD, Ignacio Lorenzo, MD, Martinez Jesus, MD, Javier De La Rubia, MD, Noemi Puig, MD, Susana Cantero, MD, Jaime Sanz, MD, Carlos Pastorini, Guillermo F. Sanz, MD, Miguel A. Sanz, MD

Blood (2005) 106 (11): 1843.

https://doi.org/10.1182/blood.V106.11.1843.1843

Published: 2005

Journal Articles

Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.

Armando V. Mena-Duran, M.D, Lyudmila A. Bazhenova, M.D., Summanuna Togo, Ph.D, Jose Cervera-Zamora, M.D., Kelly J. Bethel, M.D., Jorge Nieva, M.D., Alan Saven, M.D., Tomas Mustelin, M.D. Ph.D., Miguel A. Sanz, M.D. Ph.D

Blood (2004) 104 (11): 3430.

https://doi.org/10.1182/blood.V104.11.3430.3430

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

SHP-1 (PTPN6) Gene Supression by FLT3/ITD Defines an Aggressive Subgroup of Myeloid Malignancies.

Autologous Stem Cell Transplantation after FLAG-IDA Chemotherapy for High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemias Secondary to MDS (sAML) Does Not Improve Outcome: A PETHEMA Experience in 103 Patients.

Identification of Risk Factors for Tumour Lysis Syndrome in Patients with Acute Myeloid Leukaemia: Development of a Prognostic Score.

Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.

Email alerts

ASH Publications

American Society of Hematology

Update search

SHP-1 (PTPN6) Gene Supression by FLT3/ITD Defines an Aggressive Subgroup of Myeloid Malignancies.

Autologous Stem Cell Transplantation after FLAG-IDA Chemotherapy for High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemias Secondary to MDS (sAML) Does Not Improve Outcome: A PETHEMA Experience in 103 Patients.

Identification of Risk Factors for Tumour Lysis Syndrome in Patients with Acute Myeloid Leukaemia: Development of a Prognostic Score.

Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only